Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease

Thrombosis Research

Volumn 120, Issue 5, 2007, Pages 671-677

  Narvaez, Idoia ^a   Sagastagoitia, Jose Domingo ^b   Vacas, Marta ^a   Saez, Yolanda ^a   Lafita, Manolo ^a   Monica, Santos ^a   de Lafuente, Jesus Pablo Saez ^a   Molinero, Enrique ^b   Iriarte, Jose Antonio ^a  

^a FIDEC   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

Author keywords

Aspirin resistance; Coronary artery; Epinephrine closure time; Fibrinogen; Lipoproteins; PFA 100

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; APOLIPOPROTEIN B; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

AGED; APOLIPOPROTEINS B; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERIOSCLEROSIS; DRUG RESISTANCE; EPINEPHRINE; FEMALE; HEMOSTASIS; HUMANS; INFLAMMATION; LIPOPROTEIN(A); MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREVALENCE;

EID: 34548028974     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.12.020     Document Type: Article

References (39)

1. Agusti A., and Diogene E. Prevención primaria del infarto de miocardio con ácido acetilsalicílico. Med Clin (Barc) 122 (2004) 592-594
2. Bueno H. Infrautilización del en la prevención cardiovascular en el paciente con diabetes Mellitus. Med Clin (Barc) 122 (2004) 101-103
3. Antiplatelet Trialist' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 324 (2002) 71-86
4. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
5. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 650-1655
6. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.V. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
7. Mueller M.R., Salat A., Stangl P., Murabito M., Pulaki S., Boehm D., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78 (1997) 1003-1007
8. Favaloro E. Clinical application of the PFA-100. Curr Opin Hematol 9 (2002) 407-415
9. Jilma B., and Fuchs I. Detecting aspirin resistance with the platelet function analyzer (PFA-100). Am J Cardiol 88 (2001) 448-1449 (letter)
10. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
11. Nicholson N.S., Panzer-Dnodle S.G., Haas N.F., Taite B.B., and Szlony J.A. Assessment of platelet function assays. Am Heart J 135 (1998) 170S-175S
12. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., et al. Aspirin response and failure in cerebral infarction. Stroke 24 3 (1993) 345-350
13. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., and Mauco G. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
14. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63 (1991) 587-593
15. Feuring M., Haseroth K., Janson C.P., Falkenstein E., Schmidt B.M., and Wehling M. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100). Int J Clin Pharmacol Ther 37 (1999) 584-588
16. Andersen K., Hurlen M., Arnesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2003) 37-42
17. Buchanan M.R., and Brister S.J. Individual variation in the effects of aspirin on platelet function: implications for the use of aspirin clinically. Can J Cardiol 63 (1995) 587-593
18. Alberts M.J., Bergman D.L., Molner E., Jovanovic B.D., Ushiwata I., and Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
19. Peters A.J., Borries M., Gradaus F., Jax T.W., Schoebel F.C., and Straue B.E. In vitro bleeding test with PFA-100: Aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. J Thromb Thrombolysis 12 (2001) 263-272
20. Gresele P., Guglielmini G., De Angelis M., Ciferri S., Ciofetta M., Falcinelli E., et al. Acute, short-tem hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 41 (2003) 1013-1020
21. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L., et al. Development of aspirin resistance in persons with previous ischaemic stroke. Stroke 25 (1994) 2331-2336
22. Hung J., Lam J.Y., Lacoste L., and Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92 (1995) 2432-2436
23. Danenberg H.D., Szalai A.J., Swaminathan R.V., Peng L., Chen Z., Seifert P., et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108 (2003) 512-516
24. Szczeklik A., Musial J., and Undas A. Reasons for resistance to aspirin in cardiovascular disease. Circulation 206 (2002) 181-182
25. Csiszar A., Stef G., Pacher P., and Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fat Acids 66 (2002) 557-558
26. Friend M., Vucenik I., and Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326 (2003) 82-83
27. Dahlen G.H., Guyton J.R., Attar M., Farmer J.A., Kautz J.A., and Gotto A.M. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary heart disease documented by angiography. Circulation 74 (1986) 758-765
28. Rhoads G.G., Dahlen G., Berg K., Morton N.E., and Dannenberg A.L. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 256 (1987) 2540-2544
29. Seed M., Hoppichler F., Reaveley D., McCarthy S., Thompson G.R., Boerwinkle E., et al. Relation of serum lipoprotein(a) and Apolipoprotein(a) phenotype to coronary heart disease in patients with familiar hypercholesterolemia. New Engl J Med 322 (1990) 1494-1499
30. Miles L.A., Fless G.M., Levin E.G., Scanu A.M., and Plow E.F. A potential basis for the thrombotic risk associated with lipoprotein(a). Nature 339 (1989) 301-303
31. Hajar K.A., Gavish D., Breslow J.L., and Nachman R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339 (1989) 303-305
32. Von Hodenberg E., Pestel E., Kreuzer J., Freitag M., and Bode C. Effects of lipoprotein(a) on thrombosis. Chem Phys Lipids 67-68 (1994) 381-385
33. Mbewu A.D., Durrington P.N., Mackness M.I., Hunt L., Turhie W.H., and Creamer J.E. Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J 71 (1994) 316-321
34. Brugemann J., Van der Meer J., Hillege H.L., Van Boven A.J., Van Doormaal J.J., and de Graeff P.A. Lipoprotein(a) levels in patients with myocardial infarction treated with anistreplase: no prediction efficacy but inverse correlation with plasminogen activation in nonpatency. Int J Cardiol 45 (1994) 109-113
35. Matsuda S., Arima M., Ohigawa T., Tanimoto K., Takagi A., Kanoh T., et al. Relation between serum lipoprotein(a) residual lesion stenosis of coronary artery after myocardial infarction without reperfusion therapy. Jpn Heart J 45 3 (2004) 397-407
36. Ezratty A., Simon D.I., and Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminógen binding and activation. Biochemistry 32 (1993) 46-28
37. Malle E., Ibovnik A., Steinmetz A., Kostner G.M., and Sattler W. Identification of glycoprotein IIb as the lipoprotein(a) binding protein on platelets. Lipoprotein(a) binding is independent of an arginyl-glycyl-aspartate tripeptide located in Apolipoprotein(a). Arterioscler Thromb 14 (1994) 345-352
38. Martínez C., Rivera J., Loyau S., Corral J., González-Conejero R., Lozano M.L., et al. Binding of recombinant Apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost 85 (2001) 686-693
39. Coma-Canella I., Velasco A., and Castaño S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 101 (2005) 71-76